These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27516426)

  • 1. DMF: a promising therapeutic option in CTCL.
    Vancurova I
    Blood; 2016 Aug; 128(6):745-6. PubMed ID: 27516426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.
    Nicolay JP; Müller-Decker K; Schroeder A; Brechmann M; Möbs M; Géraud C; Assaf C; Goerdt S; Krammer PH; Gülow K
    Blood; 2016 Aug; 128(6):805-15. PubMed ID: 27268084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DMF in CTCL: where do we go from here?
    Allen PB
    Blood; 2023 Aug; 142(9):753-754. PubMed ID: 37651156
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous T Cell Lymphoma: A Difficult Diagnosis Demystified.
    Peterson E; Weed J; Lo Sicco K; Latkowski JA
    Dermatol Clin; 2019 Oct; 37(4):455-469. PubMed ID: 31466586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of clonality in cutaneous T cell lymphoma and associated diseases.
    Wood GS
    Ann N Y Acad Sci; 2001 Sep; 941():26-30. PubMed ID: 11594579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma.
    Su IJ; Tsai TF; Cheng AL; Chen CC
    J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):685-92. PubMed ID: 8227539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
    Nevala H; Karenko L; Vakeva L; Ranki A
    Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
    Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
    Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 13. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
    Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma.
    Senda N; Miyagaki T; Kamijo H; Nakajima R; Oka T; Takahashi N; Suga H; Yoshizaki A; Asano Y; Sugaya M; Sato S
    Eur J Dermatol; 2018 Oct; 28(5):621-627. PubMed ID: 30378541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
    Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
    Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in primary cutaneous T-cell lymphoma.
    DeSimone JA; Sodha P; Ignatova D; Dummer R; Cozzio A; Guenova E
    Curr Opin Oncol; 2015 Mar; 27(2):128-33. PubMed ID: 25594623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.
    Yamanaka K; Clark R; Dowgiert R; Hurwitz D; Shibata M; Rich BE; Hirahara K; Jones DA; Eapen S; Mizutani H; Kupper TS
    Clin Cancer Res; 2006 Jan; 12(2):376-82. PubMed ID: 16428475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma.
    Ohmatsu H; Sugaya M; Miyagaki T; Suga H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Br J Dermatol; 2012 Aug; 167(2):359-67. PubMed ID: 22512719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma.
    Nagatani T; Miyazawa M; Matsuzaki T; Iemoto G; Kim ST; Baba N; Miyamoto H; Nakajima H
    Semin Dermatol; 1994 Sep; 13(3):216-22. PubMed ID: 7986691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD26 expression on cutaneous infiltrates from patients with cutaneous T-cell lymphoma (CTCL) CD26 in cutaneous T-cell lymphoma patients.
    Novelli M; Comessati A; Quaglino P; Savoia P; Fierro MT; Bernengo MG
    Adv Exp Med Biol; 2003; 524():223-34. PubMed ID: 12675243
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.